University of Notre Dame
Browse
- No file added yet -

Anti-HIV group I introns and uses thereof in treating HIV infections

Download (1.17 MB)
standard
posted on 2017-08-01, 00:00 authored by Malcolm J. Fraser
Described is a unique class of antiviral molecule that can be applied to control and eliminate HIV infection in patients using myeloablation therapies and replenishment with transformed bone marrow stem cells programmed to express the antiviral molecule. These anti-viral molecules target the HIV genome in a highly conserved domain, and when expressed in cells prior to infection will cause the cell to die upon infection with HIV. Cell death insures no proliferation of new virus. Reconstituting the immune system with cells expressing these antivirals prevents re-establishment of HIV infection from reservoirs in the re-established lymphocyte and macrophage populations. Over time, reservoirs will be depleted entirely, effectively eliminating the virus. In effect, this new type of antiviral can be used to cure HIV infections.

History

Patent Number

US 9707257 B2

Other Application

13/096,626

Inventor

Malcolm J. Fraser

Inventor from Local Institution

Malcolm J. Fraser

Assignee

University of Notre Dame du Lac

Date Modified

2017-08-01

Language

  • English

Claims

24

Prior Publication Number

US 20120276071 A1

Publisher

U.S. Patent and Trademark Office

Cooperative Patent Classification Codes

A61K 35/545 (20130101); C12N 15/1132 (20130101); C12N 2310/124 (20130101); C12N 2310/3519 (20130101)

Contributor

Malcolm J. Fraser

International Patent Classification Codes

C12N 15/113 (20100101); C12N 15/12 (20060101); C12N 15/11 (20060101); A61K 35/545 (20150101)

Usage metrics

    Patents

    Categories

    No categories selected

    Keywords

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC